Related Experiment Video
Updated: Aug 14, 2026
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
DSCC1 Identified as Promising Tumor Biomarker and Potential Therapeutic Target Through Comprehensive Multi-omics
1School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, People's Republic of China.
Abstract:
As a component of the alternative replication factor C (RFC) complex, DSCC1 plays a significant role in cancer progression due to its aberrant expression. However, the potential function of DSCC1 in a pan-cancer context remains unclear. In this study, we conducted a comprehensive analysis of DSCC1's role in tumors by integrating multi-omics bioinformatics tools. First, we utilized various databases to compare the expression of DSCC1 between tumor and normal tissues, revealing a strong association between its dysregulated expression and clinical diagnosis, prognosis, and staging. Additionally, we investigated different mutation types of DSCC1 and their contributions to cancer progression, finding that DSCC1 expression is regulated by epigenetics and RNA modifications. Furthermore, we explored the correlation between DSCC1 and immune-infiltrating cells, as well as immunotherapeutic biomarkers, suggesting that its expression influences the tumor immune microenvironment. By employing single-cell and spatial transcriptome data through platforms such as SingleCellBase, CancerSEA, and CROST, we further uncovered the heterogeneity of DSCC1 across various cancer types. Finally, we validated the significant upregulation of DSCC1 mRNA in multiple tumor cell lines using q-RTPCR, and demonstrated through CCK8 assays that silencing DSCC1 expression effectively suppressed cell proliferation. Our findings establish a foundational understanding of DSCC1's potential as a biomarker for cancer diagnosis, prognosis, and immunotherapy.
Insights
DSCC1, a component of the alternative replication factor C (RFC) complex, is significantly dysregulated in various cancers. Its aberrant expression impacts cancer progression, prognosis, and the tumor immune microenvironment, suggesting potential as a diagnostic and therapeutic biomarker.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- DSCC1 is a component of the alternative replication factor C (RFC) complex.
- Aberrant expression of DSCC1 is implicated in cancer progression.
- The pan-cancer role of DSCC1 remains largely uncharacterized.
Purpose of the Study:
- To comprehensively analyze the role of DSCC1 in a pan-cancer context using multi-omics data.
- To investigate the association of DSCC1 expression with clinical features, epigenetic regulation, and immune infiltration.
- To validate the functional impact of DSCC1 on cancer cell proliferation.
Main Methods:
- Utilized multi-omics bioinformatics tools and public databases for expression analysis.
- Investigated DSCC1 mutations, epigenetic regulation, and RNA modifications.
- Analyzed single-cell and spatial transcriptome data (SingleCellBase, CancerSEA, CROST).
- Performed quantitative real-time PCR (q-RTPCR) and CCK8 assays for validation.
Main Results:
- DSCC1 dysregulation correlates with clinical diagnosis, prognosis, and staging across multiple cancers.
- DSCC1 expression is influenced by epigenetic modifications and RNA modifications.
- DSCC1 expression impacts the tumor immune microenvironment and correlates with immune-infiltrating cells and immunotherapeutic biomarkers.
- DSCC1 mRNA is upregulated in tumor cell lines, and its silencing inhibits proliferation.
Conclusions:
- DSCC1 plays a significant role in pan-cancer progression.
- DSCC1 is a potential biomarker for cancer diagnosis, prognosis, and immunotherapy.
- Targeting DSCC1 may offer a novel therapeutic strategy for cancer treatment.
